We are building a deep pipeline of potentially differentiated therapies, with the goal of advancing care and outcomes for patients with diverse inflammatory diseases
- Preclinical
- Phase I
- Phase II
- Pivotal or Phase III*
Antibody targeting IL-4Rα cytokine receptor
(Th2 cell modulator)
- Preclin
- Ph 1
- Ph 2
- Ph 3
Atopic Dermatitis (AD)
Atopic Dermatitis (AD)
Asthma
Asthma
NEXT ANTICIPATED MILESTONE
NEXT ANTICIPATED MILESTONE
Submit NDA by end of Q1’24
Secure partnership to advance Global Ph3 in 2023
Topline readout in 2H2023
Small molecule targeting S1P1
(Th1 cell modulator)
- Preclin
- Ph 1
- Ph 2
- Ph 3
Ulcerative Colitis (UC)
Ulcerative Colitis (UC)
Crohn's Disease (CD) **
Crohn's Disease (CD) **
Peripherally restricted
H3 receptor antagonist
- Preclin
- Ph 1
- Ph 2
- Ph 3
Pruritus Associated with AD
Pruritus Assoc.
with AD
*The Company’s clinical trial in China of CBP-201 in patients with AD is included as the Company intends to submit a New Drug Application in China based on the results of this trial, pending pre-NDA discussions with the Chinese Center for Drug Evaluation of the National Medical Products Administration.
**Phase 2 CD trial ended early due to COVID-19-related enrollment challenges.
- Key:
- Ongoing
- Planned